Atherosclerosis and connective tissue diseases

Joint Bone Spine

Volumn 68, Issue 6, 2001, Pages 564-575

  Meyer, Olivier ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Atheroma; Inflammation; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; CHOLESTEROL; FIBRIN; GLUCOCORTICOID; HEAT SHOCK PROTEIN 60; LOW DENSITY LIPOPROTEIN;

AGE; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONNECTIVE TISSUE DISEASE; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISEASE CONTROL; DISEASE DURATION; HEART FAILURE; HUMAN; HYPERTENSION; MORTALITY; OBESITY; POSTMENOPAUSE; RHEUMATOID ARTHRITIS; RISK FACTOR; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0035673761     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1297-319X(01)00330-X     Document Type: Short Survey

References (96)

1. Évolution des théories sur l'athérosclérose
2. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins lupus cohort
3. The bimodal mortality pattern of systemic lupus erythematosus
4. Mortality in lupus nephritis
5. Systemic lupus erythematosus - Survival patterns: Experience with 609 patients
6. A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death
7. Prevalence and mortality rates of systemic lupus erythematosus and causes of death in SLE patients in Finland
8. Mortality in systemic lupus erythematosus: The bimodal pattern revisited
9. Outcome in systemic lupus erythematosus: A prospective study of patients from a defined population
10. Ischemic heart disease in systemic lupus erythematosus. A retrospective study of 65 patients treated with prednisone
11. Prognosis in systemic lupus erythematosus: Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death
12. Lupus erythematosus in the 1980's: A survey of 570 patients
13. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis
14. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death
15. Causes of death in systemic lupus erythematosus
16. Changing patterns of mortality in systemic lupus erythematosus (SLE) over three decades at an urban center abstract
17. Morbidity and mortality in systemic lupus erythematosus during a 5-year period
18. Incidence studies of systemic lupus erythematosus in Southern Sweden: Increasing age, decreasing frequency of renal manifestations and good prognosis
19. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy : A study of 36 necropsy patients
20. Coronary arterial disease in systemic lupus erythematosus: Quantification of degree of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years
21. Morbidity in systemic lupus erythematosus
22. Immunopathology of cardiac lesions in fatal systemic lupus erythematosus
23. Manifestations cardiaques du lupus erythemateux aigu disseminé
24. Risk factors for coronary artery disease in patients with systemic lupus erythematosus
25. Dietary treatment of hyperlipidemia in patients with systemic lupus erythematosus
26. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus
27. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus
28. Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus
29. SPECT dual isotope myocardial perfusion imaging in women with SLE. I. Prevalence and distribution of abnormalities
30. Premature atherosclerosis and myocardial hypertrophy in SLE and antiphospholipid antibody (APLA) syndrome abstract
31. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus
32. Myocardial infarction (MI) and stroke in SLE: Markdedly increased incidence after controlling for risk factors abstract
33. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed fromto 1992
34. Mortality among arthritics
35. Ten year mortality and causes of death in patients with rheumatoid arthritis
36. Cause of death in rheumatoid arthritis
37. Increased mortality in rheumatoid arthritis
38. Cardiovascular mortality in women with rheumatoid arthritis
39. Rheumatoid arthritis is an independent risk factor for ischaemic heart disease abstract
40. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors abstract
41. Progression of atherosclerosis in common carotid artery (CCA) of patients with rheumatoid arthritis (RA). Thickening of intimamedia thickness (IMT) by ultrasonography abstract
42. Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients
43. Natural history of hypercholesterolemia in systemic lupus erythematosus
44. Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians
45. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis
46. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methothrexate therapy for rheumatoid arthritis: Implications for cardiovascular disease prevention
47. Pathogénèse de l'athérosclérose. Encycl Méd Chir
48. The role of macrophage scavenger receptors in atherogenesis
49. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: A report from the Committee on Vascular Lesions on the Council on Arteriosclerosis
50. Atherosclerosis. An inflammatory disease
51. Les satines préviennent-elles le risque d'accident vasculaire cérébral?
52. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
53. Statins as a newly recognized type of immunomodulator
54. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus
55. Homocysteine, Methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: A retrospective cohort study
56. Homocysteine and thrombotic disease
57. Association of serum antibodies to heat shock protein 65 with carotid atherosclersosis
58. Nouveaux marqueurs biologiques non lipidiques de l'athérosclérose
59. Infectious agents and atherosclerotic vascular disease
60. Is atherosclerosis an immunologically mediated disease?
61. Induction of atherosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65 arterioscler
62. Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein 65
63. Paraoxonase activity is dramatically decreased in patients positive for anticardiolipin antibodies
64. Atherosclerosis: The emerging role of inflammation and the CD40-CD40 ligand system
65. Perturbation of the T-cell repertoire in patients with unstable angina
66. IFNγ potentiates atherosclerosis in apoE knock-out mice
67. CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity
68. A tale of two diseases atherosclerosis and rheumatoid arthritis
69. Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies
70. Induction of early atherosclerosis in LDL-receptor deficient mice immunized with beta2-glycoprotein I
71. Accelerated atheroma and antiβ2 glycoprotein I antibodies
72. Immunolocalization of β2 glycoprotein I (apolipoprotein H) to human atheroscerotic plaques. Potential implications for lesion progression
73. Involvement of β2 glycoprotein I and anticardiolipin antibodies inoxidatively modified low-density lipoprotein uptake by macrophages
74. Fluvastatin inhibits the activation of endothelial cells induced by antiphospholipid antibodies in vitro abstract
75. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein
76. Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome
77. Antiphospholipid, antibeta 2 glycoprotein I and anti-oxidized-low-density antibodies in antiphospholipid syndrome
78. Autoantibody against oxidised LDL and progression of carotid atherosclerosis
79. Antibodies to oxidized lipoproteins and their relationship to myocardial infarction
80. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus
81. Antibody against oxidized low-density lipoprotein predicting myocardial infarction
82. T lymphocytes from human atherosclerotic plaques recognise oxidised low density lipoprotein
83. Arterial disease in lupus and secondary antiphospholipid syndrome: Association with anti-beta-2 glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein
84. Anti-oxidized low-density lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome
85. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malon-dialdehyde-modified LDL reduces atherogenesis
86. Hyperimmunization of ApoE deficient mice with homologous oxLDL suppresses early atherogenesis
87. Autoantibodies against malondialdehyde modified lipoprotein (a) in antiphospholipid syndrome
88. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE
89. Anti-apolipoprotein A-I autoantibody: Characterization of monoclonal autoantibodies from patients with systemic lupus erythematosus
90. Occupancy of Clq receptors on endothelial cells (EC) by immune complexes downregulates mRNA for sterol 27-hydroxylase (27-OH'ase), the major mediator of extra-hepatic cholesterol metabolism abstract
91. The atherogenic effect of lupus sera: Systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta
92. Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: A quality improvement study
93. Hydroxychloroquine used in Baltimore Lupus Cohort : Effects on lipids, glucose and thrombosis
94. Recommandations diététiques aux dyslipidémiques
95. Statins and the acute phase response
96. Premature atherosclerosis in systemic lupus erythematosus